DZ BANK/PUT/GILEAD SCIENCES/70/0.1/17.01.25

DZ BANK/PUT/GILEAD SCIENCES/70/0.1/17.01.25 Stock

DE000DJ88C58

Market Closed - Boerse Frankfurt Warrants 03:34:50 2024-07-05 pm EDT
0.62 ^EUR	-3.12%

Current month	+10.91%
1 month	-24.69%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart DZ BANK/PUT/GILEAD SCIENCES/70/0.1/17.01.25

Latest news about GILEAD SCIENCES, INC.

HIV Breakthrough - Drug Trial Shows Injection Twice a Year Is 100 Percent Effective Against Infection [analysis]	Jul. 03	AQ
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	Jul. 01	MT
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	Jul. 01	CI
Gilead Benefit Helps Employees Navigate Cancer Care	Jul. 01	AQ

More news

Quotes 5-day view

Date	Price	Change
24-07-05	0.61	-4.69%
24-07-04	0.64	+3.23%
24-07-03	0.62	+12.73%
24-07-02	0.55	+3.77%
24-07-01	0.53	-3.64%

Real-time Boerse Frankfurt Warrants

Last update July 05, 2024 at 03:34 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	GILEAD SCIENCES, INC.
Issuer	DZ BANK
WKN	DJ88C5
ISIN	DE000DJ88C58
Date issued	2024-02-06
Strike	70 $
Maturity	2025-01-17 (194 Days)
Parity	10 : 1
Emission price	0.31 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.93 €
Lowest since issue	0.41 €
Spread	0.01 €
Spread %	1.61%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company